Publications by authors named "S P Eholie"
Observational studies suggest a reduction in fatal or severe COVID-19 disease with the use of ACE2 inhibitors and statins. We implemented a randomized controlled tree-arm open label trial evaluating the benefits of adding telmisartan (TLM) or atorvastatin (ATV) to lopinavir boosted ritonavir (LPVr) on the SARS-CoV-2 nasopharyngeal viral load in patients with mild / moderate COVID-19 infection in Côte d'Ivoire. RT-PCR positive COVID-19 patients ≥ 18 years, with general or respiratory symptoms for less than 7 days were randomized (1:1:1) to receive LPVr (400 mg/100 mg twice daily), LPVr + TLM (10 mg once daily) or LPVr + ATV (20 mg once daily) for 10 days.
View Article and Find Full Text PDFBackground: Due to the low number of individuals with HIV-2, no randomised trials of HIV-2 treatment have ever been done. We hypothesised that a non-comparative study describing the outcomes of several antiretroviral therapy (ART) regimens in parallel groups would improve understanding of how differences between HIV-1 and HIV-2 might lead to different therapeutic approaches.
Methods: This pilot, phase 2, non-comparative, open-label, randomised controlled trial was done in Burkina Faso, Côte d'Ivoire, Senegal, and Togo.
Article Synopsis
- People with HIV (PWH) treated for tuberculosis (TB) may develop a condition called TB-associated immune reconstitution inflammatory syndrome (TB-IRIS) after starting antiretroviral therapy (ART), which includes integrase inhibitors like raltegravir and non-nucleoside reverse transcriptase inhibitors like efavirenz.
- A study analyzed data from the Reflate TB 2 trial, which compared the occurrence of TB-IRIS in PWH receiving either raltegravir or efavirenz-based ART while undergoing standard TB treatment.
- The results showed that the incidence of TB-IRIS was similar in both ART groups, with 48 participants developing TB-IRIS, and identified risk factors such as low CD4
Objectives: Detailed simulation models are needed to assess strategies for prevention and treatment of hepatitis B virus (HBV) infection, the world's leading cause of liver disease. We sought to develop and validate a simulation model of chronic HBV that incorporates virological, serological and clinical outcomes.
Methods: We developed a novel Monte Carlo simulation model (the HEPA-B Model) detailing the natural history of chronic HBV.
Background: This analysis evaluated the immune response to the two-dose, heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola virus vaccine regimen, administered 56-days apart, from multiple African sites based on results from one analytic laboratory.
Methods: Immunogenicity across three trials (EBL2002, EBL2004/PREVAC, EBL3001) conducted in East and West Africa is summarised.